NCT02636842

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Alkermes, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.

Conditions

• Schizophrenia
• Schizoaffective Disorder

Interventions

Type	Name	Description
DRUG	Aripiprazole Lauroxil	Intramuscular (IM) injection, single dose

Timeline

• Start date: 2015-12-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2015-12-22
• Last updated: 2016-07-14

Locations

6 sites across 1 country: United States